Introduction
Stroke is a vascular disease with cerebral consequences, where the heart is a key player. It is defined as 'a clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting more than 24 h or leading to death, with no apparent causes other than of vascular origin'. 1 The incidence of stroke varies between 100-400 per 100 000 per year 2 and mortality ranks second after coronary heart disease. 3 Beyond mortality stroke is the largest single cause of physical disability in adults, second cause of dementia (after Alzheimer disease), major cause of depression, falls and epilepsy in the elderly. Stroke hence presents a tremendous burden both on patients as well as families and health care systems. Despite decreasing mortality rates in recent years, 4 hospitalization numbers are increasing 3 and long-term care and secondary prevention of stroke will have to move even more in the focus of clinical and health economic efforts. Most strokes (85%) are ischaemic and 15-20% are haemorrhagic. At least 25% of ischaemic strokes are of definite cardio-embolic origin and about a further 20-25% are of suspected cardiac origin or involvement. Most importantly, stroke is clearly recognized as a preventable disease. Stroke patients tend to have pre-existing cardiovascular comorbidities both diagnosed and not at stroke presentation. It is thus inherently logic, that prevention and treatment is an interdisciplinary challenge and should be carried out 'hand-in-hand' by neurologists (experts on the brain and cranial vessels) and cardiologists (experts on the heart and peripheral vessels). Recent advances in the diagnosis and treatment of stroke and also of many conditions predisposing to stroke further underline the need for close cooperation of a wide range of medical specialties: neurology, cardiology, neuroradiology, neurosurgery, vascular surgery, intensive care, diabetology, internal medicine, etc.
This article summarizes the views and aims of the recently founded European Society of Cardiology (ESC) Council on Stroke focusing on the role of cardiologists in comprehensive and state of the art stroke treatment, as in, prevention, diagnosis, rehabilitation, and long-term care of stroke.
Cardiologists role in stroke prevention
Primary and secondary stroke prevention Stroke prevention includes the screening for and active influencing of all known risk factors: hypertension, cardiac disease (including arrhythmias), smoking, obesity/diet/physical inactivity, diabetes mellitus, alcohol, stress/depression ( Figure 1 , Table 1) . 5 Environmental and behavioural factors are clearly associated to the risk of stroke and may well contribute to the considerable differences in stroke prevalence numbers with a north-south as well as east-west gradient across Europe. Secondary stroke prevention, by contrast, may rest particularly with the specialist medical health care provider and includes the screening for and both the monitoring and treatment of all risk factors. Optimum preventive measures may only be assured when the etiology of stroke is being investigated and targeted. Cardiovascular causes of stroke pose naturally a high risk of other cardiovascular events and strong efforts to detect and to effectively treat such causes are imperative beyond mere stroke prevention. Notably, 1 year after stroke the cardiac causes are the major causes of mortality in these patients. 6 Effective cardiac diagnostic workup after stroke (not just during the subacute post-stroke period) is, however, still lacking in most routine clinical practice despite the general understanding of the heart-brain relationship in stroke. Specialists tend to be over focused on their predefined roles. That is, cardiac patients are often at risk of subsequent stroke and vice versa stroke patients are often at risk of myocardial infarction, heart failure, or sudden cardiac death. Information on the antithrombotic, antihypertensive, antiarrhythmic, hypolipidaemic, and other medication administered during hospital stay and prescribed at discharge needs to be shared between neurologists and cardiologists. Unfortunately, in most European health care systems there is no specialized long-term follow-up and care for stroke patients as this is well established for other chronic diseases. In fact, the discharged stroke patients are often referred to their general practitioners (GP) without consulting the other specialty medical care (cardiology or neurology). It may be worthwhile to ask patients about their sleeping habits as sleep-related breathing disorders may be important risk factor for cardiac or vascular diseases including stroke.
Secondary stroke prevention should be focused on all risk factors in general, but also focus on the (presumed or proven) aetiology (or predisposing condition) of the stroke in each individual patient. Since ischaemic stroke is just one presentation of arteriosclerotic diseases this event highlights the importance of global assessment of vascular risk and the necessity to promote lifestyle modifications and consequent medical treatment post stroke ( Figure 1) . 7 Despite the fact that asymptomatic coronary artery disease (CAD) is common among stroke survivors, 8 incidence of myocardial infarction is low in the 1st year post-stroke, 9 and routine screening for CAD is not recommended. 10 Stroke patients with previous symptomatic CAD, patients with abnormal cardiac work-up and those with very highvascular risk (large-vessel atheromatous ischaemic stroke, diabetes mellitus, renal failure, etc) should have a cardiology follow-up. Other risk factors such as hyperlipidaemia, hypertension, diabetes, and vascular diseases may be newly diagnosed at the time of the stroke. Therapeutic measures to target these comorbidities may be commenced during the index hospital stay. However, full therapeutic doses and complete work-up may usually not be achieved during the initial hospitalization and subsequent follow-up and further diagnostic and therapeutic steps might be required to achieve the full potential of secondary preventive strategies. The often complex treatment regimen including medical as well as interventional and behavioural strategies requires interdisciplinary concepts and the need for specialized care. The current understanding of stroke is increasing to realize stroke as a chronic disease and stroke patients as chronic patients requiring continued monitoring and medical care. Patient education is of major importance in this context.
Stroke prevention through hypertension treatment
Hypertension needs a special focus as it is related to both aetiologic types of stroke (i.e. ischaemic and haemorrhagic) via multiple direct and indirect mechanistic pathways (Figure 2) . High blood pressure in the intracranial arteries may contribute to intracranial bleeding particularly at weak spots such as aneurysms and other vascular malformations. All types of ischaemic stroke are strongly correlated to high blood pressure levels. Moreover, hypertension also promotes white matter lesions leading to silent brain infarctions. Detailed functional and psychological testing may reveal that such lesions are in fact not fully silent but account for accumulating functional and cognitive deficits. Indirect effects of hypertension on the brain may further add to the very high risk of stroke in these patients. The high pressure in the left ventricle and the left atrium (always present in patients with very high systemic pressures) contributes to the atrial dilatation, fibrosis, myopathy, and heart failure and thus promotes atrial fibrillation (AF) and clot formation. 11 Effective treatment of hypertension is known to substantially decrease the stroke rates.
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Therapeutic intervention on blood pressure has clearly to be divided between the acute stroke phase and subsequent post-stroke blood pressure control. In the acute ischaemic stroke higher than normal blood pressure is accepted if not pursued in order to achieve sufficient intracranial perfusion pressure. A cochrane analysis including 26 trials and 17 011 participants could not show that actively lowering blood pressure in the acute phase of stroke improves functional outcome. 15 In fact, lowering blood pressure in the 1st hours after ischaemic stroke is harmful. Ideal blood pressure range during acute ischaemic stroke will depend on the stroke subtype and other patient specific comorbidities. Some studies found a U-shaped relation between the admission blood pressure and favourable clinical outcomes, with an optimal systolic blood pressure ranging from 121 to 200 mmHg and diastolic blood pressure ranging from 81 to 110 mmHg. However, elevated inhospital blood pressure during acute ischaemic stroke has been associated with worse clinical outcomes in a more linear fashion. 16 Treatment regimen in patients with established cardiovascular disease needs specific attention and considerate adjustment. Plain withdraw of beta blocking therapy in patients with heart failure or coronary artery disease may cause undesirable rebound effects putting even more strain to the myocardium in the acute condition.
After the acute phase hypertension should be targeted as a risk factor for further vascular damage and recurring events. Initiation of antihypertensive therapy within 24 h of stroke is relatively safe. Restarting antihypertensive medications is reasonable after the first 24 h for patients who have pre-existing hypertension and are neurologically stable. 17, 18 No data are available to guide selection of medications for the lowering of blood pressure in the setting of acute ischaemic stroke. 16 
Stroke prevention in atrial fibrillation
Atrial fibrillation is known to be associated with increased risk of ischaemic stroke. However, despite the clear pathophysiologic concept of AF to account for clot formation in the left atrium and the cardio-embolic genesis of stroke it is a continued matter of debate whether AF is really the cause of stroke or just a risk marker. Particularly the demonstrated temporal disconnect between AF episodes and the stroke fuel this discussion. 19 Increasing awareness of the role of unrecognized AF should accelerate efforts to detect AF before stroke has occurred and institute effective thromboprophylaxis with long-term oral anticoagulants. 20 Many studies demonstrated that a longer electrocardiogram (ECG) monitoring leads to a higher detection of paroxysmal AF. [21] [22] [23] The annual detection rate is between 10 and 15%. This highlights the importance of long-term ECG monitoring for all patients who survived ischaemic stroke with undetermined aetiology. Moreover, there is accumulating evidence that most strokes of undetermined origin are in fact, thromboembolic: recently, the Cryptogenic Stroke and Underlying Atrial Fibrillation (CRYSTAL-AF) and the 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event (EMBRACE) trials reported that previously unknown paroxysmal AF can be detected in a significant proportion of cryptogenic strokes. 22, 23 Until today, however is has been shown that long-term ECG monitoring can detect AF. Whether this results in a lower risk of stroke has yet to be proven. Other potential sources of embolism in cryptogenic stroke include the mitral and aortic valves, the left cardiac chambers, proximal cerebral arteries of the aortic arch, and the venous system via paradoxical embolism. Accordingly, a new clinical construct termed embolic stroke of undetermined source (ESUS) was recently introduced by the Cryptogenic Stroke/ESUS International Working Group as a potential therapeutic relevant entity with an indication for anticoagulation. 24 Cryptogenic ischaemic strokes (ESUS) comprise about 25% of all ischaemic strokes. Embolic strokes of undetermined source may represent a future indication for anticoagulation. 24 This is being tested in ongoing randomized trials.
Comprehensive diagnostic approach may rationalize the indications to anticoagulant therapy and maybe also to non-pharmacological measures in secondary stroke prevention. It is important to consider AF in patients at risk (e.g. by palpating the pulse in all patients > 65 years visiting the GP 25 ). Screening of (silent) AF may even be considered at a lower age in the presence of a higher risk (CHA 2 DS 2 -VASc > _ 2 in individuals > _ 55 years). Although the yield of long term monitoring in higher risk populations certainly will be higher, it is uncertain whether it also is cost-effective. Furthermore, the significance of short AF runs detected during long-term monitoring remains to be established.
Stroke prevention in structural heart disease
Valvular disease (including prosthetic valves), congenital heart disease (including patients after surgical repair), patent foramen ovale (PFO), atrial septal aneurysm, infective endocarditis, cardiomyopathies, left ventricular aneurysms, intra-cardiac tumours, and other cardiac pathologies are frequent cause of AF and/or stroke. The highest risk is related to the presence of a prosthetic valve or to rheumatic mitral stenosis. It is less known, that also aortic stenosis and any form of heart failure poses an increased risk of stroke if is accompanied by AF. Patent foramen ovale is discussed later in this text. 
Contribution of cardiologists to the diagnosis of stroke
Early diagnosis of stroke is essential to keep the chance for recovery realistic. Acute stroke is a treatable disease, as long as it is treated as a hyperacute emergency where every minute counts-e.g. similar emergency as to trauma, bleeding, or myocardial infarction ( Table 2) . Diagnosis of stroke is based on clinical history, neurologic examination and brain imaging and is generally the domain of neurologists and imaging specialists (usually neuro-radiologists). The role of cardiologists in the early diagnosis of stroke (first few hours) is minimal. However, cardiologists should play an important role during the subsequent hours to days, when early recognition of potential underlying and/or associated cardiac disease may contribute to the aetiologic diagnosis of stroke. Especially echocardiography and ECG monitoring are important methods in this respect ( Table 2 ). This plays a critical role in those patients who reach functional recovery after strokediagnosis and treatment of underlying heart disease may prevent stroke recurrence. Cardiologists should be therefore part of the stroke interdisciplinary teams in comprehensive stroke centres (usually located in large tertiary hospitals, where all involved specialists are available 24 h a day, 7 days a week) as well as in stroke units. 26 As an example, patients with symptomatic intracranial atherothrombosis are at high risk of myocardial infarction within the following months.
Therapeutic approaches to stroke prevention and treatment

Antithrombotic medication
Antithrombotic (i.e. antiplatelet or anticoagulant) treatment should not be used in the acute phase (24 h) of stroke for tPA-treated patients, but it is of utmost importance for secondary prevention after ischaemic stroke. Further studies on determining optimal indications, dosage, timing, and drug selection are needed to better specify in whom antiplatelet therapy should be instituted, in whom anticoagulation therapy is better, when (how many days after stroke) such therapy should be started, etc. Obviously this depends also on the underlying cardiac condition. In general aspirin should be initiated within 24-48 h after uncomplicated ischaemic stroke (if the stroke is of vascular atherosclerotic-not cardioembolic-origin), while the optimal time for (re-)starting oral anticoagulants (e.g. in AF) has to be refined. The ESC guidelines recommend to postpone oral anticoagulants at least one or few days (transient ischaemic attacks or mild ischaemic strokes) up to 6-14 days (in moderate to severe ischaemic strokes) after stroke onset. 25 Subcutaneous (low molecular) or i.v.
heparin in full dose conferred no net benefit in patients with ischaemic stroke (the risk of haemorrhage was higher than the reduction in recurrent stroke) and therefore should not be used. 27, 28 Low dose LMWH should be used for deep venous thrombosis/pulmonary embolism prophylaxis after stroke. Any antithrombotic regimen used in the acute phase of stroke raises the risk of haemorrhagic transformation of the cerebral infarct and the benefit of the intensity and the duration of treatment should be weighted against the risk of bleeding. Recent trials in Asian population are in favour of double antiplatelet therapy in the first three months post minor stroke or transient ischemic attack (TIA), especially for patients with intra-or extracranial atheromatous symptomatic stenosis. 29 For the time being, long-term single antiplatelet therapy with aspirin or clopidogrel remains the mainstay of secondary stroke prevention in non-cardioembolic stroke. The advent of novel anticoagulants has provided a safe anticoagulation option for cardioembolic stroke patients that were moderately or poorly controlled by vitamin-K antagonists (VKA). Anticoagulation in patients with any type of AF is firmly established. In patients with heart failure and maintained sinus rhythm, by contrast, the decision on optimum antithrombotic therapy is less clear. While increased risk of thrombus formation develops with heart failure, the benefit of VKA anticoagulation is outweighed by the increased bleeding risks. 30 Further studies are under way to test the efficacy of novel oral anticoagulants (NOACS) in this setting. For more information on this matter we address the interested reader to the recently updated European Heart Rhythm Association practical guide for use of the non-VKA oral anticoagulants 31 that addresses also the issue of anticoagulation initiation post ischaemic and haemorrhagic stroke.
Endovascular treatment and catheterbased thrombectomy
The recent advances in interventional treatment of acute stroke [32] [33] [34] [35] [36] established catheter-based thrombectomy (on top of best medical therapy) as class IA indication for the treatment of anterior circulation stroke (Figure 3) caused by emergent large vessel occlusion presenting within <6 h from symptom onset. 37, 38 The DAWN trial (presented during ESOC 2017, publication pending) showed that with the use of sophisticated magnetic resonance imaging, the therapeutic time window can be extended to 24 h. Currently, over 10% of stroke patients are eligible for endovascular treatment but future research and clinical experience will have to prove the full potential of this treatment.
A number of questions emerged from the recent trials that will be addressed in future studies: those include questions on logistics and timing as well as procedural issues, patient selection, concomitant treatments and others. One multisociety consensus document proposed general standards for hospital requirements and physician qualifications for performing endovascular stroke interventions. 39 The authors recognize that the implementation of such standards need to account for a wide variety of national clinical standards and procedural requirements. Further evaluation and interdisciplinary communication are needed to define on the basis of national and local requirements how physicians with related experience such as interventional cardiologists with carotid stenting (CAS) experience may be adequately trained for endovascular thrombectomy. Ongoing and future trials and interdisciplinary communication may answer these unresolved questions. 40 
Carotid stenting
Open carotid endarterectomy (CEA) and stenting have been extensively studied for primary stroke prevention (outside the acute phase of stroke) and after transient ischaemic attacks or minor strokes (modified Rankin scale 0-2). Both methods are effective in preventing future (larger) stroke. 41 Carotid stenting and carotid endarterectomy and similarly effective for patients <70 years old, whereas for older patients CEA appears to be the best option. Ideally, the procedure should be done within 2 weeks of the patient's last symptomseither shortly after TIA or minor stroke. 42 These treatments are covered extensively by the ESC Guidelines on Peripheral Artery Disease. 43 The role of CAS in the acute phase of stroke (on top of thrombectomy)
is not yet well established. 44 
Patent foramen ovale closure
Patent foramen ovale has been extensively studied as a cause of cryptogenic stroke. Patent foramen ovale is highly correlated with cryptogenic stroke especially in younger patients and when atrial septal aneurysm is also present. 45 Previous trials have failed to demonstrate PFO closure superiority to medical treatment, thus moderating initial enthusiasm about this invasive procedure. 46 Closure of a PFO for secondary prevention of cryptogenic embolism did not result in a significant reduction in the risk of recurrent embolic events or death as compared with medical therapy. 47 In one study, closure was superior to medical therapy alone in the pre-specified per-protocol and astreated analyses, with a low rate of associated risks. 48 However, very recently two additional randomized trials on PFO closure have been presented during the European Stroke Organization Conference 2017: CLOSE and GORE REDUCE trials. Both trials were highly significantly positive supporting PFO closure in patients younger than 60 years with large PFO and atrial septal aneurysm. Thus, it seems likely that this will be reflected in future guidelines. Clinical scores have been developed to aid the clinician decide which patient would mostly benefit of the procedure. 49 Joint consultation of neurologists and cardiologists is important to select the right patients. The role of closure procedures in majority of PFO patients who have a small risk of stroke under best medical therapy remains to be established. 50 The individual patient data meta-analysis 51 presented evidence that PFO closure prevents recurrent stroke and is in agreement with CLOSE and GORE REDUCE trials.
Pulmonary veins isolation
The recent advances in the interventional treatment of AF (e.g. pulmonary veins isolation) have been shown to decrease the risk of AF recurrence. It remains to be demonstrated, whether these ablation procedures may also impact on the risk of stroke. Ablation procedures do not obviate the need of anticoagulation in high-risk patients: anticoagulation of all patients should be pursued for 3 months postprocedure, whereas for high-risk patients it should continue indefinitely. 52 Additionally, many patients with AF are elderly with other co-morbidities and there is limited information on the risk/benefit of these procedures in this population. More trials are needed in these older (and increasing) at risk populations. Implementation of atrial ablation in rate vs. rhythm control trials might change outcomes in favour of rhythm control therapy but this effect has not yet been shown. The Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST; ClinicalTrials.gov, number NCT01288352) and the Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA; ClinicalTrials.gov, number NCT00911508) randomly assigned patients to rate control or early atrial catheter ablation. Outcomes in cardiovascular morbidity and mortality will be available within several years. These trials will provide contemporary results as to whether catheter ablation of AF is accompanied by reduction of morbidity and mortality. If these trials report positive results, guidelines for treatment of AF and the choice between rhythm control and rate control might change.
Left atrial appendage occlusion or removal
Left atrial appendage (LAA) occlusion is emerging as a possible alternative to anticoagulation for patients carrying very high bleeding risk, especially those that have already suffered intracranial haemorrhage because of anticoagulation. It might be a future alternative for patients at high risk of stroke with simultaneous high risk for bleeding. In two studies patients with device implanted into the LAA had fewer haemorrhagic strokes, but more ischaemic strokes compared with warfarin. The role of this method has yet to be established. [53] [54] [55] One study, comparing LAA ocluders versus novel oral anticoagulant apixaban is ongoing. 56 Other ongoing studies in AF patients with contraindications for long term anticoagulation compare LAA occlusion with standard of care.
Conclusion
Cardiologists should be interested and involved in the prevention, diagnosis, and treatment of stroke ( Table 3) . The aim of cardiologists should be to help other specialists (neurologists, stroke physicians, radiologists, neurosurgeons, etc.) to improve the outcomes of stroke patients and to decrease the risk of stroke among those, who are at risk for stroke. In some areas (e.g. diagnosis and treatment of AF, diagnostic workup to uncover the cardiac cause of stroke) the role of cardiologists is essential, while in other areas the role of cardiologists currently is rather complementary. Only intense interdisciplinary cooperation may improve the poor outcomes of stroke patients and to decrease the burden of stroke in population.
Key messages
• Stroke is a multi-system disease that requires the systematic incorporation of cardiologic expertise in preventive, diagnostic, and therapeutic workup of patients in order to
• identify patients at higher risk • establish causes and relevant comorbidities • identify and treat acute and subacute cardiovascular complications
• ensure comprehensive and continued monitoring and treatment of risk factors.
• Stroke units are a major concept of acute stroke care and the structured inclusion of cardiologic expertise in conceptual organization of stroke units may be recommended.
• Stroke patients are chronic patients that require continued and life-long supervision and treatment of risk factors and stroke sequelae including both neurologic and cardiologic expertise.
• Catheter-based thrombectomy is the most effective treatment of acute ischaemic stroke when performed timely by an experienced team.
